Cell homogenate from stem cells derived from growing deer antlers, a method of obtaining it and its use

ABSTRACT

The subject of the present invention is a bioactive cell homogenate produced from cells belonging to the MIC-1 stem cell line derived from growing deer antlers (Cervidae) deposited at the DSMZ under the accession DSM ACC2854, a method of producing and using it. The present invention also encompasses a pharmaceutical or cosmetic composition containing the above-mentioned homogenate.

This application is a §371 national stage application of PCTInternational Application No PCT/PL2009/050003, filed Jan. 26, 2011, thecontents of all of which are hereby incorporated by reference into thisapplication.

The subject of the present invention is a cell homogenate obtained fromstem cells from growing deer antlers, a method of obtaining it and itsuse. The subject of the present invention is also a pharmaceutical orcosmetic composition containing the above-mentioned cell homogenate.

There have been many known attempts in the state of the art to isolateand produce stable stem cell lines, from which it would be possible tomake stable preparations for various uses.

The disclosed solutions relating to obtaining stem cells thatdifferentiate into osteoblasts are derived solely from various types ofhuman tissue. Applications WO 2005/085422 and US 2005/0048644 disclosestem cells isolated from adipose tissue used in the treatment of muscleand skeletal diseases. Application W0 2005/038012 discloses a method ofobtaining stem cells capable of differentiating into osteoblasts orchondroblasts from human postnatal tissue. Application US 2007/0122902discloses a method of isolating and culturing multipotent stem cellsobtained from umbilical blood. Attempts have also been made togenetically modify cells capable of regenerating cartilage and bonetissue, which were disclosed in patent description U.S. Pat. No.6,398,816. The greatest ethical controversy concerns applicationsrelating to stem cells obtained from embryonic tissue (W0003068937,WO02064755, WO000385831).

The use of human stem cells widely described in prior art entails manyproblems which are evidence of the strong need to conduct furtherresearch in this area. Some of the main obstacles entailed by the use ofembryonic cells are ethical questions, the danger of the occurrence ofgenetic defects as well as the risk of transferring viral and oncogenicdiseases. There is thus a strong need for stem cell lines whose usewould eliminate the risk of the above obstacles.

Prior art discloses the properties of deer antler tissue which isrecognized as the most rapidly growing form of bone among mammaliantissues. Attempts have been made to make use of the proliferativeproperties of this tissue, especially through the isolation of growthfactors. Application W093/19085 discloses a method of isolating a growthfactor that is a substance capable of regenerating damaged bone tissue.A method is disclosed of obtaining an extract isolated from the antlersof the Japanese deer (Cervus nippon) which stimulates the proliferationof hematopoietic stem cells and megakaryocytes. Application WO2004/112806 discloses a composition for the treatment of neuronaldisorders made from growth hormone markers obtained from deer antlers.

In 2005, the authors of the present invention began to research thegrowth process of the antlers of the noble deer (Cervus elaphus). Inthose experiments, the MIC-1 stem cell line was derived from the growingdeer antlers. The MIC-1 stable cell line was deposited at the DSMZ(Deutsche Sammlurll Von Mikroorganismen Und Zellkulturen, Inhoffenstr. 7B, D-38124 Braunschweig) under the accession DSM ACC2854 on Jul. 16,2007. In 2006, a patent application was made, P 378963, whose subjectsincluded the novel stem cell line MIC-1 from growing deer antlers, theuse of terminal lateral fragments of growing deer antlers in theproduction of a stable stem cell line was well as the use of these cellsin the reconstruction of bone and cartilage lesions in humans andanimals. Currently, one of the main directions of research is the searchfor sources of a preparation for stimulating regenerative processes incomplex organs such as the skin. Research on the physiology of aging andregeneration processes in tissues has led to the discovery of the roleof stem cells it these processes.

The goal of the present invention is to deliver a preparation andproducts based on stem cells, which have a beneficent effect on theregeneration of skin and the reconstruction of its elements.

Unexpectedly, it turned out that this cell homogenate from cells of theMIC-1 stem cell line exhibits particularly beneficial activity instimulating the growth and regeneration of diseased or damaged elementsof the skin.

The subject of the present invention is cell homogenates obtained by thedestruction of cells from the MIC-1 stem cell line derived from thegrowing deer antlers (Cervidae) deposited at the DSMZ under theaccession DSM ACC2854.

Preferably, the destruction of the cells and the homogenates isperformed using ultrasounds. Destruction of antlerogenic stem cellsreleases active substances contained therein, which activateregenerative processes.

In a preferable embodiment of the present invention, one unit of thehomogenate comprises the extract from 1 million cells.

The next subject of the present invention is a method of obtaining abioactive cell homogenate, characterized in that cells are cultured andare subsequently separated from the medium, disrupted using ultrasounds,wherein the cells used are cells of the MIC-1 stem cell line derivedfrom growing deer antlers (Cervidae) deposited at the DSMZ under theaccession DSM ACC2854.

Preferably, in the method according to the present invention, the cellsare cultured on plates or in suspension.

Preferably, in the method according to the present invention, astandardised homogenate is produced which comprises the extract obtainedfrom 1 million cells in one unit.

The next subject of the present invention it is a pharmaceutical orcosmetic composition which comprises an active ingredient and apharmaceutically permissible carrier, characterized in that the activesubstance is the homogenate of cells from the MIC-1 stem cell linederived from growing deer antlers (Cervidae) deposited at the DSMZ underthe accession number DSM ACC2854.

Preferably, the composition is meant for intradermal or topicalapplication.

The advantages of the present invention are, first of all, standard cellculture conditions and cells with a high proliferation potential, aswell as the absence of ethical considerations, which are usually broughtup against research on human embryonic cells.

Another subject of the present invention is the use of a homogenateobtained from cells from the MIC-1 stem cell line derived from growingdeer antlers (Cervidae) deposited at the DSMZ under the accession DSMACC2854, in the production of a preparation for the medical and cosmetictreatment skin.

Preferably, the preparation is designed for topical or intradermalapplication.

The skin, as an enclosing organ, is particularly susceptible to diseasesand trauma due to its protective function. Repair processes occur in itthroughout life. Due to its biostimulant properties, the extract isuseful in broadly defined regenerative medicine and cosmetology. Thecell homogenate from cells from the MIC-1 cell line has a beneficialeffect on epithelium formation, stimulates the healing of wounds andskin lesions, activates hair follicles, stimulates the production ofcollagen fibers, augments the proliferation of fibroblasts and activatestissue vascularization. The MIC-1 line stem cell homogenate exhibitsproperties that influence the regeneration of skin and its biorenewalwhich it make it possible to reconstruct age-related deterioration. Thecell homogenate and preparations made on its basis are widely applicableas anti-wrinkle agents, lifting and anti-aging agents which regenerateskin damaged by solar radiation, revitalize the skin by increasing itstenderness and elasticity, as well as cosmetics for the maintenance ofmucous membranes.

Furthermore, the cell homogenate and preparations made on the basis arewidely useful as agents for the treatment of difficult to heal woundsarising, for example, as a result of diabetes, shin ulcerationsresulting from the vascular disease such as vain disorders, Renodisease, as well as agents for attenuating radiation damage and skindamage following chemotherapy.

The cell homogenate constituting the subject of the present inventionand the preparation made on its basis are further useful in aestheticmedicine, dermatology and in sports medicine, particularly as agents forstimulating regeneration following acne, for healing burns and forhealing vascular disorders following trauma.

The subject of the present invention is useful in as a biostimulatingpreparation for the mucous membranes, particularly in relation toparadontosis, mucous membrane ulceration, for example in the oralcavity, the nose and the vagina. The cell homogenate being the subjectof the present invention, as well as preparations made of it are alsouseful in veterinary medicine in the acceleration of healing and hairregrowth.

The next subject of present invention is a new use for the cellhomogenate produced using the disruption of cells from the MIC-1 stemcell line derived from growing deer antlers (Cervidae) deposited at theDSMZ under the accession DSM ACC2854 in the production of a preparationfor the regeneration of tissue selected from among muscle, nervous andepithelial tissue.

Preferably, the preparation is used in the form of drops for the eyes,an ointment for the eyes, and injectable preparation or a preparationfor saturating spongostan.

Preferably, the composition of the eyedrops ecomprises, per milliliter,the homogenate at a rate of 10 U/ml, 50 mg or 10 U/ml 25 mg as well asancillary substances.

Preferably, the ancillary substances are selected from a groupcomprising polyvinyl alcohol, disodium hydrogen phosphate, sodiumdihydrogen phosphate, sodium chloride, benzalkonium chloride, and water.

Preferably, the eye ointment contains the module at a rate of 10 U/ml 50mg, an injectable preparation comprises the homogenate at a rate of 10U/ml 100 mg, and a preparation for saturating spongostan comprises thehomogenate at a rate of 10 U/ml 100 mg.

BRIEF DESCRIPTION OF DRAWINGS

The subject of the present invention is shown in the Figures, where FIG.1 shows the effect of MIC-1 cell homogenate on the proliferation of:fibroblasts (F), myocytes (M), chondrocytes (CH) and hepatocytes (H).Fibroblasts—MIC-1 homogenate (F+HMIC-1), myocytes−MIC-1 homogenate(M+HMIC-1), chondrocytes−MIC-1 homogenate (CH+HMIC-1), hepatocytes−MIC-1homogenate (H+HMIC 1), FIG. 2 represents the surface of the lesion inpixels following the use of a drop with a concentration of 0.5 millioncells/ml of preparation, FIG. 3 represents the surface of the lesion inpixels following the administration of a drop with a concentration of0.5 million cells/ml of preparation FIG. 4A represents an uncoverednerve following 12 weeks of observation, FIG. 4B shows the isolatedneuron, visible seams connecting the implants with stubs, FIG. 5represents a control group 12 weeks, implantation of the ischiadic nervein the rat, FIG. 6 represents the control group following 12 weeks,implantation of the ischiadic nerve in the rat, FIG. 7 represents theexperimental group following 12 weeks, peripheral regeneration of theimplant, FIG. 8 represents the experimental group 12 weeks following theoperation, peripheral regeneration of the implant, FIG. 9 shows theexperimental groups following 12 weeks, nervous fibers in the center ofthe implant, FIG. 10 shows the path length in centimeters and rest timein seconds of a mouse following 180 s of video recording, FIG. 11A showsan image of the muscle immediately following the lesion, FIG. 11Brepresents an image of the muscle following 14 days after the use of thehomogenized, FIG. 11C shows an image of the muscle immediately followingthe lesion, FIG. 11D shows an image of the muscle following 14 days ofthe use of the medium, FIG. 12A shows an animal from the experimentalgroup: image of an almost unchanged skeletal muscle—final stages ofhealing, FIG. 12B shows the experimental group, fully regeneratedskeletal muscle, lengthwise cross-section. The lesion that had beenincurred is confirmed by individual nuclei located in the centralportion of the muscle fibers, FIG. 13A represents the control groupwhere myotubes and a forming scar are visible after the tissue wascrushed, FIG. 13B represents an animal from the control group,regenerating damaged muscle, at the center there is a visible scar withresorbing tissue and giant cells, FIG. 14A represents a tangentialsection of the skin following a 21 day application of dermal homogenate,visible is an increased number of secondary hairs in hair follicles aswell as numerous present bundles of collagen fibers, FIG. 14B representsa control tangential section of skin following 21 days application ofphysiological saline (control), FIG. 15 represents a parallel section ofthe derma following 21 day application of intradermal homology. VanGieson staining shows newly formed collagen fibers, FIG. 16 shows thewound that had healed in the fifth 24-hour period following theisolation of a tissue section which encompassed all layers of the skin,

The subject of the present invention as also shown in exampleembodiments which do not limit the scope of its protection.

EXAMPLE 1 Production of the Homogenate Containing Mesenchymal MIC-1 StemCells from Deer Antlers

The culture is maintained in an incubator under standard conditions, ata temperature of +37° C. and an atmosphere containing 5% CO₂.Antlerogenic cells are adhesive, and grow in 175 ml flasks (BD Falconcell culture flask) in MEM culture medium from Cambrex which contains10% fetal bovine serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin.The efficiency from one bottle is about 30 million cells per 14 dayculture cycle. After a full monolayer is obtained, the cells aredetached from the flask bottom using 0.05% trypsin with 0.02%ethylenediaminotetraacetic acid (EDTA) and transferred to centrifugetubes. The tripsin in the centrifuge tubes is inactivated by adding 10ml of supernatant. The cells are then washed twice in PBS andcentrifuged off. Centrifugation is performed in a Heraeus centrifuge for10 minutes at about 1000 RPM. The supernatant is decanted off aresulting in a cell pellet. This is suspended in 0.9% sodium chloride ata rate of 1 billion cells per 50 ml of liquid. The homogenous suspensionis cooled in a water cooled homagenisation chamber to a temperature ofabout 4° C. In the steel chamber, with continuous cooling, ultrasoundsare used at a frequency of 20 kHz for 30 seconds to disrupt the cells(Ultrasonic disintegrator UD-20, Techpan). The solution is scaled inbiological units, one unit represents the extract obtained from 1million cells. The homogenate is stored frozen at −80° C.

EXAMPLE 2 Production of a Form of the Cell Homogenate ContainingMesenchymal Stem Cells MIC-1 from Deer Antlers

The preparation based on the cell homogenate may occur in the form of anointment, cream, tonic or any other form suitable for topicalapplication. The preparation may also have dermal uses. An example of anointment base is Hascobase or any other known and commonly used ointmentbase used by specialists such as Lekobaza, anhydrous eucerine,cholesterol ointment or Vaseline (Farmacja stosowana. red. StanislawJanicki i Adolf Flebig, PZWL Warszawa 1996). 10 g of suspensioncontaining 50 units of homogenate were supplemented with 40 g of medium.The mixture was homogenized using a semiautomatic mixture, PA 200 Alpinea (Poland). Homogenization was performed over five minutes in adedicated container, 50 ml volume, on automatic settings.

At tonic was prepared, where 50 ml of 96% ethanol were supplemented with50 ml of suspension containing 100 biological units of the homogenate.The resulting preparations were stored in cool conditions.

EXAMPLE 3 Examination of the Effect of the Cell Homogenate on the SkinFollowing a Single Topical or Intradermal Dose

The evaluation of the effect of the cell homogenate on the skinfollowing a signle topical or intradermal administration was conductedon 2 of 4 groups containing 6 individuals each selected from a group of24 white New Zealand rabbits.

During the topical administration, 6 cm² of depilated, undamaged skin onone side of the rabbit (in the area of the rib cage,) were treated with0.5 ml of the preparation. The same surface on the other side (control)was treated with the appropriate medium. The site of administration wasexamined over 96 hours.

During intradermal administration, 6 cm² of desolated, undamaged skin onone side of a rabbit (in the area of the rib cage) was injected at amarked site intradermally with 0.5 ml of the preparation. The markedsite on the other side of the rabbit was injected with 0.5 mlphysiological saline, and the condition of the skin was evaluated after96 hours.

Following the single dose, we observed a slight blushing of the skinstarting on the second day of observation, which ended after 10 days.Both forms were tolerated well.

EXAMPLE 4 Evaluation of the Effect of the Cell Homogenate on the SkinFollowing Multiple Topical and Intradermal Administration

The evaluation of the effect of the homogenate cell on the skinfollowing multiple topical or intradermal administration was conductedon 2 of 4 groups containing 6 individuals each selected from a group of24 white New Zealand rabbits.

During the topical administration, 6 cm² of depilated, undamaged skin onone side of the rabbit (in the area of the rib cage) were treated with0.5 ml of preparation, once daily over 28 consecutive days. An identicalsurface on the other side control was treated with the appropriatemedium in the same way as the examined preparation. The administrationsite was controlled multiple times over the first 8 hours of treatment,and then daily for the next 21 days.

During intradermal administration, 6 cm² of depilated, undamaged skin onone side of the rabbit (in the area of the rib cage) were treated with0.5 ml of preparation once daily over 14 consecutive days. The samesurface on the other side, control, was treated with an appropriatemedium in an identical mode as the exam preparation. The site ofadministration was controlled multiple times over the first 8 hours oftreatment and then daily over the next 21 days.

On the 14th day of observation in 6 animals from the multipleadministration groups, we collected skin sections for histologicalevaluation from locations with intensive hair growth. In 3 animals fromthe control group, tissue sections from the sites where thephysiological saline was administered were collected for histologicalevaluation. Administration of the homogenate intradermally did not causeany damage to the skin and was well tolerated. In the preparations, weobserved an increased number of hairs in the growth phase as compared tothe control group, as well as a thickening of the hair around the hairbulb. In the derma, we observed an increased number of collagen fibers.These processes were observed most clearly in the group receiving theMIC-1 cell homogenate intradermally.

The patches of skin which were treated with the cells exhibited fasterhair regrowth than areas treated with physiological saline. Visibledifferences were observed on the 6th day of observation. Complete hairyregrowth to its proper length for a given individual, meaning from 35 to42 mm, occurred after about 10 to 14 weeks. Hair growth during 2-3 weekswas accelerated and amounted to about 4 mm per week. No noticeablegrowth was observed in the control group. Subsequently, the growth was2-3 mm per week. Administration of the homogenate intradermally causedno damage to the skin and was well tolerated. Histological preparationsfollowing the application of the homogenate, as compared to the controlgroup, resulted in the considerable growth of secondary hair and anincrease in the number of newly synthesized collagen fibers.

EXAMPLE 5 Evaluation of the Effect of an Ointment Based on the MIC-1Stem Cell Homogenate

The evaluation was performed on 9 rabbits divided into 3 groups of 3animals each, using 3 types of ointment of various concentrations: 1 U/1g of Hascobase, 0.5 U/1 g of Hascobase as well as 0.1 U/1 g ofHascobase. Group 1 rabbits were treated with the 1 U/1 g ointment, group2 was treated with the 0.5 U/1 g ointment and group 3 was treated with0.1 U/1 g. All groups were treated according to the following procedure:6 cm² of depilated, undamaged skin on one side of the rabbit (in thearea of the rib cage) were treated with 0.5 ml of preparation once dailyover 28 consecutive days. The same surface on the opposite side(control) was treated with the appropriate medium (Hascobase) in thesame way as the examined preparation. The site of administration wascontrolled multiple times during the first 8 hours followingadministration and then daily over the next 28 days.

No intensified hair growth was observed in the group receiving the 0.1U/1 g ointment. The group treated with the 0.5 U/1 g ointment.Accelerated hair growth was observed on about the 26 day postapplication. The largest concentration was active on about the 21st datepost application.

We measured blood flow in the skin in rabbits of group 1, both on thetreated and controlled sides.

The measurement was made using a laser Doppler flow meter, and MBF3D(Moor Instruments Ltd) and a P4s probe, 0.46 mm in diameter. The deviceemits monochromatic light at a wavelength of 780-820 nm that is producedby a semiconductor laser, 1.5 mW of power. The Doppler laser method isbased on the emission of monochromatic optical radiation into tissuesand detection of dispersed light which returns to the surface of thetissue. During the dispersal of light on erythrocytes which are moving,the frequency of the wave changes depending on the speed of theerythrocytes and the angle made by the path of the erythrocytes and thephoton (Doppler phenomenon). An appropriate detection device with asignal converter and analyzer makes it possible to collect informationregarding the blood saturation of a given tissue, defined as the productof the local blood velocity and the concentration of erythrocytesaveraged per the volume of tissue where the light penetrates. Blood flowmeasurements in one area of the skin spanned a minute. The analysis wasperformed on the slowest 20 second flow interval. The extent of bloodflow, the perfusion, was expressed as the product of the concentrationof erythrocytes and their velocity using a relative unit (perfusionunit). A 47% increase of blood perfusion in skin was observed incomparison to control skin.

The use of the ointment on the skin was well tolerated. We observed aninsignificant hyper-perfusion in the area of the application, and themore rapid regrowth of hair on the side where the ointment or tonic wasused. Wounds at the sites where tissue samples were collected forhistology healed much more rapidly than on the control side.Histological analysis demonstrated similar changes as in the groupreceiving the homogenate as an injection.

EXAMPLE 6 In Vitro Evaluation

In vitro studies showed that the substances contained in the velvet andin deer antler extract stimulate the proliferation of fibroblasts,splenocytes and hematopoietic stem cells. Taking into account thepresence of blood vessel muscles in antlers, we also evaluated theeffect of the homogenate of antlerogenic cells on fibroblasts(connective and epithelial tissue), smooth muscle cells (muscle tissue),chondroblasts (connective tissue), hepatocytes (epithelial tissue) andneurons (nervous tissue).

For this study, we used the following reference cell lines: mouseembryonic fibroblasts (3T3 Balb/c) and human myocytes from the embryonicaorta (UASMC). The primary chondroblast culture was derived frommechanically disrupted rabbit ear cartilage fragments (white Californiarabbit female of about 4 kg body weight). To set up the primaryhepatocyte culture and neuron culture we used organ fragments collectedfrom a neonatal rat (Wistar), which were mechanically disrupted andincubated in smooth muscle growth medium (Cambrex Bio Science,Walkersville Md. USA). The myocytes were cultured in smooth musclegrowth medium, whereas the remaining cell lines in DMEM (Bio Whittaker,Lonza, Verviers, Belgium) within the addition of 10% fetal bovine serumand 1% of a solution containing L-glutamine, penicillin and streptomycin(Sigma-Aldrich, Chemie, Steinheim, Germany). The cultures weremaintained at 37° C. in a moist atmosphere containing 5% CO₂. The timeneeded to achieve 70% confluence in a culture flasks (75 ml) was: 5 daysfor myocytes and neurons, 10 days for fibroblasts and chondroblasts, and21 days for hepatocytes. The evaluated cells were removed from cultureflasks using a solution of 0.25% trypsin-EDTA (Sigma Aldrich) andre-inoculated at 100,000 cells per well on 12 well plates. After 24hours, the medium was exchanged and a homogenized suspension of MIC-1cells was added at a dose of 0.2 units (1 biological unit equals thehomogenate obtained from 1 000 000 MIC-1 cells). The plates wereincubated for 120 hours after which time the cells were photographed andcounted using the SRB colorimetric test (where the SRB test determinesthe number of living cells that bind a die, sulphorhodamine B). Thecells were fixed with 50% trichloroacetic acid and then stained with0.4% SRB in 1% acetic acid for 30 minutes. Unbound dye was removed byrinsing in 1% acetic acid and the died bound to proteins of the cellswas extracted with 10 mM unbuffered Tris. Optical density was then readon an Elx-800 plate reader (Bio-Tek instruments, USA) at a wavelength of562 nm. The sample control consisted of the same medium as used in theprocedure. All of the reagents for the tests were purchased from Sigma.

To evaluate the significance of the differences between the individualgroups of the results we used the Student's t-test and as statisticallysignificant we accepted p<0.05. All statistical analyses were performedusing the Statistica 7.1 package from Statsoft.

The biggest increase in proliferation was obtained for fibroblasts andmyocytes, because there numbers grew by a respectively 32 and 28%. Inthe culture of Contra blasts with the homogenate of MIC-1 sells therewas a 19% increase in the number of hunger blasts as compared to thosecultured without in the addition of the homogeny. A similar situmulatinginfluence of the homogenate was observed on hepatocytes whose numbergrew by 16% compared to have data sites not treated with it (FIG. 1).These differences were always statistically significant. No increase inthe number of cells was observed for neurons treated with thehomogenate. After 120 hours of incubation of all cell types with thehomogenate they exhibit no signs of aging (shrinkage) as was observed inthe case of cells not treated with the homogenate.

The mesenchymal stem cells (MSC) introduced into damaged tissueparticipate in its regeneration, and after several weeks fromadministration there remains only a small number of them which leads tothe conclusion that the regeneration is the result of factors secretedby the MSC which modulate the microenvironment at the site of thelesion, and in this way inducing the survival and proliferation of inthe endogenous host cells. The above-mentioned factors include proteinsregulating hematopoiesis, angiogenesis, healing, immune response as wellas the mobilization and proliferation of hematopoietic stem cells. Asimilar mechanism was observed following the administration ofantlerogenic stem cells into cartilage lesions in the ear and jawbone inthe rabbit. The reconstructed tissues contained concentrations ofundifferentiated stem cells, which underwent apoptosis over time.Likewise, the individual studies confirm the influence of the MSC on thesurvival and secretory activity of other cells. The participation ofMIC-1 cells in the regeneration of damaged tissues as well as thedescribed stimulatory influence of the substance contained in antlers onthe proliferation of cells and the acceleration of healing of breakageshas led us to study the influence of the homogenate of MIC-1 cells onvarious types of cells in vitro. The results obtained indicate theconsiderable stimulation of the proliferation of fibroblasts andmyoblasts by the homogenate of MIC-1 cells as well as a smallerinfluence on the proliferation of chondroblasts and hepatocytes. Onlyfor the neurons was there no increase in the observed number duringculturing with an addition of the homogenate. Nevertheless, thesurvivability of cells increased threefold, and the neurons, in additionto increasing their size, developed a dense net of mutualinterconnections. Cell cultures with an addition of antlerogenic cellhomogenate thereby create new opportunities in regenerative medicinefacilitating the possibility of obtaining enough material to fill inlesions in any tissue.

EXAMPLE 7 In Vivo Assay, Epithelial Tissue (Cornea)

In this study we used 12 rabbits, young 8-month females of the NewZealand white variety, weighing from 2.5 to 2.9 kg. During theexperiment, the animals were kept in individual cages with unlimitedaccess to food and water in a 12 hours light:12 hours dark cycle. Priorto beginning the experiment, all of the rabbits had their eyes examinedso as to eliminate any extant disorders of the cornea or the conjunctivaas well as the remaining structures of the anterior eyeball (anteriorchamber and iris). We conducted a fluorescein assay (evaluation of theanterior portion following the administration of a 2% fluoresceinsolution to the conjunctiva using a cobalt filter) and evaluation usingthe slot lamp. No irregularities were observed. In each animal, one eyewas examined and the other eye constituted the control. The abrasion ofthe corneal epithelium was performed in the following way. After localanaesthesia with a solution of Alcaine (proxymethacaine hydrochloride, 5mg/ml, Alcon) the corneal epithelium was damaged in both eyes of eachrabbit through the application of a disk, 3 mm across, of Whatman #1tissue soaked in n-heptanol (Sigma Aldrich). The disc was applied to thecenter of the cornea and left in place for 30 seconds following itsremoval the eye was rinsed with isotonic saline, 0.9% NaCl. Throughoutthe experiments, in 6 rabbits, the right eyes (experimental eye) weretreated 3 times per day at equal intervals (every 8 hours) until thelast day with the homogenate at a concentration of 0.5 U/ml (number 1eyedrops) (3 eyes) and 0.25 U/ml (number 2 eyedrops) (3 eyes) at a rateof 3 drops. One biological unit equals the homogenate obtained from 1000 000 MIC-1 cells, which corresponds to 1 mg of cell mass placed in100 mg of distilled water. The left eye, constituting the control, wastreated in the same pattern and volume using the medium. In another 6rabbits, we used the homogenate in the form of an ointment in the sameconcentration as the drops. These were administered in the same patternsto each eye, in the form of a lump of ointment the size of a peppercorn.The evaluations encompassed corneal damage and the rate of itsregeneration in the examined group (2×6 animals) in comparison to thecontrol. To evaluate the rate of healing of lesions in the eye in therabbits, the eyes were stained with a 2% solution of fluorescent andexamined with a 10 hour interval between the damage and the initiationof the measurements. This time corresponds to the lag phase in thehealing of the cornea observed in vivo. The eyes were examined using aslot lamp, and we also performed the fluorescent assay and photographs(photographic documentation) on all of the experimental and controlcorneas. The photographs were made during every 10 hours post trauma.The surface of the damaged area of the cornea was measured in pixels,analyzing the size of the lesion using the Adobe Photoshop CS Extendedpackage. The results obtained were averaged to evaluate the decrease ofthe wound surface over time. The experiment terminated with theacquisition of 100% wound closure in the cornea in both groups, both theexperimental and control. The results were gathered in Table 1 as wellas FIG. 2 demonstrating the surface of the damage in pixels followingthe administration of a drop with a concentration of 0.5 millioncells/ml of preparation, Table 2 and FIG. 3 represent the data for thedamage surface in pixels following the administration of the ointment ata concentration of zero decimal 5 million cells/ml of preparation.

TABLE 1 Right Left eye eye time average SD average SD 0 10 195735 11690197212 4883 24 178169 10004 316094 15551 48 15175 981 95291 5462 72 019987 1885 82 0 0

TABLE 2 Right Left eye eye time average SD average SD 0 10 196968 11639201174 8293 24 169675 12902 292304 13688 48 16110 4860 92942 12295 72 019133 2534 82

In all eyes which were treated with the preparation (drops or ointment)containing the MIC-1 homogenate, the healing occurred much more rapidly.In the first 24 hour period after the treatment no increases wereobserved in the damaged areas. Complete healing occurred before thelapse of 72 hours of observation. The beneficial influence of bothpreparations was approximately equal. The preparations with a lowerconcentration of homogenate exhibited an efficacy decreased by about athird.

EXAMPLE 8 In Vivo Assay, Nervous Tissue (a Ski Attic Nerve)

In these experiments we used young (2 to 3-month-old) Wistar rats ofboth sexes, weighing from 240 to 310 grams During the experiment, theanimals were maintained in cages with unlimited access to water and foodin a light/dark cycle of 12:12. The experimental group consisted of 4animals and the control group of 3 animals (1 rat died during theexperiment, failed to wake from anesthesia). The animals were operatedunder full anaesthesia with an intraperitoneal injection of ketamine andxylazine at a dose of 75/5 mg/kilograms body weight. We operated using amicroscope and microsurgery tools under as septic conditions. Followingdepilation and desinfection with Octenisept ((Schulke&Meyr GmbH,Norderstedt, Germany), the area was surrounded with sterile tissue. Theincision of about 2.5 cm was made lengthwise on the external portion ofthe thigh. After separating the layers of the thigh muscles, blunt toolswere used to make the ischiatic nerve visible, which is located betweenthe rear and interior thigh muscles and the shank of the thigh bone. Thenerve was freed over a length of 1.5 cm and a 1 cm fragment of its axiswas cut out. The excised portion of the nerve was reimplanted,connecting both stubs at both ends by applying two non-dissolvingepineural sutures of 4/0 nylon monofilament MEDICO (SHJIAZHUANG)INDUSTRIES AND TRADE CO., LTD. underneath the implant, we placed a flakeof Spomgostan, an absorbable gelatin sponge produced by Johnson &Johnson, Warsaw Poland, sized 1 by 0.5 cm which had been saturated withthe cell homogenate at a concentration of one unit per 1 mm of 0.9%NaCl. The incision was sutured as a monolayer, the skin was againdisinfected would have walked on a set and left uncovered. In thecontrol group weaves on the spam soaked only with 0.9% NaCl. Thepostoperative recovery and all animals was correct the wounds healedwith primary adhesions and the skin suture was removed on the 7th dayfollowing the procedure. We observed a markedly more rapid healing ofwounds in the experimental group. After 12 weeks the animals weresacrificed by the administration of thiopental added at a rate of 120mg/kg. Microsurgery was used to isolate the nerve that had been operatedon, collecting its fragment which encompassed the proximal fragment, theimplant and the distal fragment (FIGS. 4A and 4B). The isolated implantwas divided into 3 parts and placed in a 4% solution of bufferedformalin. Comparing the results from the control group (FIGS. 5, 6) andthe experimental group (FIGS. 7, 8, 9), the significant difference ofthe regeneration of the nerve in that implant pertained to the peripheryof the nerve fiber but the bundle at the sites were the gelatin spongesaturated with MIC-1 cell homogenate was placed. At the sites weobserved the activation and stimulation of pairing mural cells and anincreased number of fine blood vessels. Peripherally, in the nervebundles there are many myelinated and unmyelinated axons, which areevidence of the process of the restitution the continuity of nervefibers (FIGS. 7, 8). In the central portions of the implants there areless frequent myelinated axons (FIG. 9).

EXAMPLE 9 In Vivo of Valuation. Muscle Tissue (Triceps)

In this experiment we used a young, 3-month-old BALB/c mice weighing 18to 22 g each. The animals were divided into 2 groups of 4 mice, andexperimental and a control group. Mice from both groups were operatedunder anesthetic (intraperitoneal ketamine and xylazine at a rate of50/5 mg/kg). After shaving and disinfecting the skin with Octenisept,the lengthwise incision uncovered the fine muscles. The hamstring wasdamaged by crushing an area of about 3×3×3 mm for 30 seconds withsurgical calipers with a pressure of about 80 kg/cm². The skin wassutured as a monolayer and the wound was disinfected with Octenisept andleft uncovered. The animals from the experimental group were given 7doses of 0.5 ml of cell homogenate at a concentration of 1 U/ml ofpreparation in the area of the incurred lesion. The first intramuscularinjection was performed immediately following the crushing and then at48 hour intervals. In the control group, in the same pattern, we usedwater for the injection. The healing always occurred correctly. Thesutures were taken out on the 7th day following the surgery. We observeda markedly more rapid regeneration of the wounds in the experimentalgroup over 2 weeks, as evaluated using the locomotor activity of themice. For this purpose we used the Smart 2.5.20 package (on the 5th,10th and 15th day following the surgery). Table 3 and FIG. 10 show thelength of the pathway in centimeters and the rest time in seconds ofmice during 180 seconds of video recording.

TABLE 3 Experimental group Control group Path length Rest time Pathlength Rest time Initial data 1875 32 2146 30  5 day 1250 61 980 75 10day 1380 34 1154 77 15 day 1740 48 1352 58

By the same token, we observed that there was higher locomotor activityand shorter rest times in animals receiving homogeny injections. After 2weeks (on the 15th day) we collected a fragment of the muscle from theregenerating area to evaluate it histologically. During the preparation,we microscopically observed that the damaged areas in the experimentalgroup were smaller in every case than in the control group (FIG.11A-11D). These observations confirmed that the behavioral studyresults. The collected fragments were placed in 4% buffered formalin.They were used to prepare histological slides. Compared to the controlgroup, in all animals receiving the homogenate in the lesion site weobserved a complete regeneration (FIGS. 12A, 12B, 13A, 13B).

The in vitro and in vivo experiments confirm unequivocally thebeneficial effect of the homogenate on the regenerateive processes inall tissues. This preparation should thus find many uses as a universalagent for stimulating the regeneration of tissues and organs. It isworth the of mentioned that these processes occur without scarring.

The invention claimed is:
 1. A method of obtaining a bioactive cellhomogenate comprising disrupting cells separated from media withultrasound, wherein the cells are cells of MIC-1 stem cell line derivedfrom growing deer antlers (Cervidae) deposited at the DSMZ under theaccession number DSM ACC2854.
 2. The method according to claim 1,further comprising culturing the cells in a plate or suspension culture.3. The method according to claim 1, further comprising producing ahomogenate titer which comprises the extract obtained from 1 millioncells in one unit.
 4. A pharmaceutical or cosmetic compositioncomprising: an effective amount of a homogenate produced from cells ofthe MIC-I stem cell line derived from growing deer antlers (Cervidae)deposited at the DSMZ under the accession DSM ACC2854, and an ointmentbase.
 5. The composition according to claim 4, wherein the activeingredient is a homogenate comprising extract from 1 million cells. 6.The composition according to claim 4, for topical or intradermaladministration.
 7. The composition of claim 4, which is a pharmaceuticalor cosmetic composition.
 8. A method for the regeneration of tissueselected from among nervous, epithelial and muscle tissue in a subjectin need thereof comprising administering to the subject the compositionof claim
 7. 9. A method for saturating spongostan in the eye of asubject comprising administering to the subject the composition of claim4.
 10. The method according to claim 9, wherein the composition is inthe form of eye drops or an eye ointment comprising the homogenate at aconcentration of 0.5 U/ml to 0.25 U/ml, wherein U unit is a unit ofhomogenate obtained from 1 million cells.
 11. The method according toclaim 10, wherein the composition further comprises polyvinyl alcohol,disodium hydrogen phosphate, sodium dihydrogen phosphate, sodiumchloride, benzalkonium chloride, water or a combination thereof.